Deals In Depth: June/July 2013
Executive Summary
In a regional deal, AstraZeneca licensed rights to FibroGen’s renal candidate in an alliance worth $815 million; Elan finally agreed to an $8.3 billion takeover by Perrigo; biopharma financing totaled $7.1 billion and $2 billion in June and July, respectively, while device fundraising reached $325 million and $316 million in the same months.
You may also be interested in...
HBW Product Launches: VitaFusion Goodness, Colgate Zero, Tom’s Prebiotic, Gaia Hemp & Herb
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.
High-Priced Entries Drive 17% Rise In Spending On Anti-Inflammatory Drugs
But declines in other categories held overall spending on US retail pharmacy drugs covered by commercial plans to a marginal 2.3% increase in 2019, Express Scripts reports.
High-Priced New Entries Drive 17% Rise In Spending On Anti-Inflammatory Drugs
But declines in other categories held overall spending on US retail pharmacy drugs covered by commercial plans to a marginal 2.3% increase in 2019, Express Scripts reports.
Need a specific report? 1000+ reports available
Buy Reports